Buy Tymlos (abaloparatide) Online For Sale

Description

What is the purpose of Tymlos (abaloparatide)?

Tymlos (abaloparatide) is an analogue of human parathyroid hormone-related peptide [PTHrP(1-34)] which is used to treat postmenopausal women with osteoporosis who are at high risk for fractures.

How does Tymlos (abaloparatide) function?

Abaloparatide is an agonist at the PTH1 receptor (PTH1R) which is similar to PTHrP(1-34) analog. In osteoblasts, this receptor is expressed on the surface. These cells are responsible for bone synthesis. By binding to these receptors, Abaloparatide initiates important processes in target cells which are expected to promote an increase in bone density and strength.

Where is Tymlos (abaloparatide) approved?

The Food and Drug Administration (FDA), USA, issued approval for Tymlos (abaloparatide) on April 28, 2017, for the treatment of patients with osteoporosis at high risk for fracture.

Please note that Tymlos may also have been approved in other countries. For further information on its approval in specific regions, please contact our support team.

What is the recommended dosage for Tymlos (abaloparatide)?

The standard dose of Tymlos (abaloparatide) is an 80 mcg subcutaneous injection administered once daily into the periumbilical region of the abdomen. If dietary intake is insufficient, patients should receive supplemental calcium and vitamin D.

Warning:

Tymlos use is not recommended for patients at high risk for osteosarcoma. The lifetime cumulative use of Tymlos and parathyroid hormone analogues (e.g., teriparatide) for more than two years is not advised.

Complete information on Tymlos (abaloparatide) dosage and administration can be found in the official prescribing information listed in our references section.

Note: Please seek advice from your treating physician for individualized dosing.

What are the known side effects of Tymlos (abaloparatide)?

Common side effects of Tymlos (abaloparatide) include hypercalciuria, dizziness, nausea, headache, palpitations, fatigue, upper abdominal pain, and vertigo, as stated in the prescribing information.

Serious side effects listed in the prescribing information include Orthostatic Hypotension, Hypercalcemia, Hypercalciuria, and Urolithiasis.

For a comprehensive list of side effects and adverse reactions, please refer to the official prescribing information.